dc.contributor.author | Hazard, Riley H. | |
dc.contributor.author | Kagina, Peninah | |
dc.contributor.author | Kitayimbwa, Richard | |
dc.contributor.author | Male, Keneth | |
dc.contributor.author | McShane, Melissa | |
dc.contributor.author | Mubiru, Dennis | |
dc.contributor.author | Welikhe, Emma | |
dc.contributor.author | Moore, Christopher C. | |
dc.contributor.author | Abdallah, Amir | |
dc.date.accessioned | 2024-06-06T08:50:59Z | |
dc.date.available | 2024-06-06T08:50:59Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Hazard, R. H., Kagina, P., Kitayimbwa, R., Male, K., McShane, M., Mubiru, D., ... & Abdallah, A. (2019, April). Effect of Empiric Anti–Mycobacterium tuberculosis Therapy on Survival Among Human Immunodeficiency Virus–Infected Adults Admitted With Sepsis to a Regional Referral Hospital in Uganda. In Open Forum Infectious Diseases (Vol. 6, No. 4, p. ofz140). US: Oxford University Press. | en_US |
dc.identifier.uri | http://ir.must.ac.ug/xmlui/handle/123456789/3711 | |
dc.description.abstract | Background: Mycobacterium tuberculosis is the leading cause of bloodstream infection among human immunodeficiency virus (HIV)–infected patients with sepsis in sub-Saharan Africa and is associated with high mortality rates.
Methods: We conducted a retrospective study of HIV-infected adults with sepsis at the Mbarara Regional Referral Hospital in Uganda to measure the proportion who received antituberculosis therapy and to determine the relationship between antituberculosis therapy and 28-day survival. Results: Of the 149 patients evaluated, 74 (50%) had severe sepsis and 48 (32%) died. Of the 55 patients (37%) who received antituberculosis therapy, 19 (35%) died, compared with 29 of 94 (31%) who did not receive such therapy (odds ratio, 1.34; 95% confidence interval [CI], .56–3.18; P = .64). The 28-day survival rates did not differ significantly between these 2 groups (log-rank test, P = .21). Among the 74 patients with severe sepsis, 9 of 26 (35%) who received antituberculosis therapy died, versus 23 of 48 (48%) who did not receive such therapy (odds ratio, 0.58; 95% CI, .21–1.52; P = .27). In patients with severe sepsis, antituberculosis therapy was associated with an improved 28-day survival rate (log-rank test P = .01), and with a reduced mortality rate in a Cox proportional hazards model (hazard ratio, 0.32; 95% CI, .13–.80; P = .03). Conclusions: Empiric antituberculosis therapy was associated with improved survival rates among patients with severe sepsis, but not among all patients with sepsis. | en_US |
dc.description.sponsorship | University of Virginia Global Infectious Diseases Institute | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | In Open Forum Infectious Diseases | en_US |
dc.subject | Africa | en_US |
dc.subject | Mycobacterium tuberculosis | en_US |
dc.subject | Sepsis | en_US |
dc.subject | Uganda | en_US |
dc.title | Effect of Empiric Anti–Mycobacterium tuberculosis Therapy on Survival Among Human Immunodeficiency Virus–Infected Adults Admitted With Sepsis to a Regional Referral Hospital in Uganda | en_US |
dc.type | Article | en_US |